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Brain tumour stem cells (BTSCs) are a small population of cells that has self-renewal, transplantation, multidrug resistance and
recurrence properties, thus remain novel therapeutic target for brain tumour. Recent studies have shown that peroxisome
proliferator-activated receptor gamma (PPARg) agonists induce growth arrest and apoptosis in glioblastoma cells, but their effects on
BTSCs are largely unknown. In this study, we generated gliospheres with more than 50% CD133þ BTSC by culturing U87MG and
T98G human glioblastoma cells with epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF). In vitro treatment with
PPARg agonist, 15-Deoxy-D
12,14-Prostaglandin J2 (15d-PGJ2) or all-trans retinoic acid resulted in a reversible inhibition of gliosphere
formation in culture. Peroxisome proliferator-activated receptor gamma agonists inhibited the proliferation and expansion of glioma
and gliosphere cells in a dose-dependent manner. Peroxisome proliferator-activated receptor gamma agonists also induced cell cycle
arrest and apoptosis in association with the inhibition of EGF/bFGF signalling through Tyk2-Stat3 pathway and expression of PPARg in
gliosphere cells. These findings demonstrate that PPARg agonists regulate growth and expansion of BTSCs and extend their use to
target BTSCs in the treatment of brain tumour.
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Brain tumours are the most devastating cancers that present
unique challenges to therapy and pose major health problems in
the United States and other parts of the world. There are over 100
different types of brain tumours identified in humans that show
widely divergent biological and clinical outcomes. Among them,
glioblastoma is the most frequent primary malignant brain tumour
in adults. Median survival is generally less than 1 year from the
time of diagnosis, and even in most favourable situations, patients
die within 2 years (Deorah et al, 2006). Standard therapy for
glioblastoma consists of surgical resection to the extent that is
safely feasible, followed by radiotherapy and chemotherapy, which
have significant side-effects and limited efficacy (Peacock and
Lesser, 2006). Targeted molecular therapies with improved efficacy
and reduced toxicity have been developed, but still face many
challenges (Kim and Glantz, 2006). Despite recent advances in
surgery, radiation, chemotherapy and other molecular therapies, a
cure for brain tumours remains elusive. The multidrug resistance
and fast recurrence are some of the challenges in combating brain
tumours, which warrant further investigation on identifying novel
molecular targets and therapeutic strategies for successful treat-
ment of brain tumours in patients.
The neural stem cells (NSCs) are a small population of cells
present in the subventricular zone that can proliferate, migrate and
differentiate into neuro-glial cells in adult CNS (Mokry et al, 1996;
Shihabuddin et al, 1999; Uchida et al, 2000). Although NSCs have
unlimited potential to treat brain diseases (Groves et al, 1993;
Lundberg et al, 1997; Rogister et al, 1999; Pluchino et al, 2003), it is
believed that these resident stem cells are the potential source of
brain tumours (Stupp and Hegi, 2007). The existence of cancer
stem cells has been suggested for breast, prostate, colon and brain
cancer. Failure to cure cancer has been attributed to the fact that
typical therapies target rapidly proliferating tumour cells, which
respond transiently, whereas sparing the tumour stem cells that
has high tumorigenic potential (Bao et al, 2006). Recent studies
have demonstrated the presence of CD133þ brain tumour stem
cells (BTSCs) that has self-renewal, transplantation and metastasis
properties in culture and in animal models (Singh et al, 2004).
Brain tumour stem cells are considered responsible for the
resistance and recurrence of brain tumours after radiation and
chemotherapy in patients (Singh et al, 2004; Bao et al, 2006; Stupp
and Hegi, 2007). However, there is no treatment available that can
successfully target BTSCs in patients.
Nuclear receptors are a family of ligand-dependent transcription
factors that mediate responses to steroids, retinoids, thyroid
hormone and vitamin D and play key roles in development and
regulation of inflammatory responses (Blumberg and Evans, 1998).
Retinoic acid (RA) is a vitamin A derivative that activates RAR/
RXR complex and induces neuro-glial differentiation of stem cells
(Guan et al, 2001). Peroxisome proliferator-activated receptor
(PPAR) is a member of the family of nuclear receptor transcription
factors composed of three known subtypes PPARa, PPARg and
PPARd (Kliewer et al, 1992). Peroxisome proliferator-activated
receptor gamma is expressed in many different tissues and
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sregulates lipid metabolism, glucose homoeostasis, tumour pro-
gression and inflammation. Several fatty acids and ecosanoids
function as physiological ligands for PPARg. The 15-deoxy D
12,14-
prostaglandin J2 (15d-PGJ2) is a natural ligand and thiazolidine-
diones, such as ciglitazone, are synthetic agonists for PPARg
(Forman et al, 1995; Lehmann et al, 1995). Upon activation with
specific ligands, PPARg heterodimerizes with RXR and induces
gene expression associated with cell growth and differentiation.
Peroxisome proliferator-activated receptor gamma agonists
regulate adipogenesis and prevent obesity. Peroxisome proliferator-
activated receptor gamma agonists also modulate glucose metabo-
lism and insulin sensitivity, thereby reducing plasma glucose and
insulin levels in type 2 diabetes (Schwartz et al, 1998). Peroxisome
proliferator-activated receptor gamma agonists attenuate the
clinical symptoms of colitis, arthritis, atherosclerosis, myocarditis,
sepsis and multiple sclerosis in animal models (Kawahito et al,
2000; Claudel et al, 2001; Natarajan et al, 2003).
Interestingly, recent studies have shown that PPARg is expressed
in normal and malignant human brain and that treatment with
PPARg agonists induces growth arrest and apoptosis in brain
tumour cells in vitro and in animal models in vivo (Strakova et al,
2004, 2005; Cellai et al, 2006; Grommes et al, 2006), but their
effects on BTSCs are unknown. In this study, we show that PPARg
agonists inhibit growth and expansion of CD133þ BTSCs as
gliospheres in culture, further suggesting its use in the treatment of
brain tumour.
MATERIALS AND METHODS
Reagents
The murine recombinant epidermal growth factor (EGF) and basic
fibroblast growth factor (bFGF) were purchased from Chemicon
International (Temecula, CA, USA). 15-Deoxy-D
12,14-Prostaglandin
J2 (15d-PGJ2) and ciglitazone were purchased from Calbiochem
(La Jolla, CA, USA). Antibodies specific to Tyrosine kinase 2
(Tyk2), signal transduction and activator of transcription 3 (Stat3),
PPARg and b-actin were purchased from Santa Cruz Biotechnology
Inc. (Santa Cruz, CA, USA). The HRP-conjugated secondary Abs,
all-trans retinoic acid (ATRA) and other chemicals were purchased
from Sigma Chemicals Co. (St Louis, MO, USA). The anti-CD133
antibody conjugated with phycoerythrin (PE) and the isotype
control were purchased from Miltenyi Biotec (Auburn, CA, USA).
DeadEndt Fluorometric Tunel system was purchased from
Promega, (Madison, WI, USA). Annexin-V-Fluos was purchased
from Roche (Indianapolis, IN, USA).
Cell culture
The U87MG and T98G brain tumour cell lines, established from
human glioblastoma were obtained from American Type Culture
Collection (ATCC, Manassas, VA, USA). The cells were cultured
in Dulbecco’s modified Eagle medium (DMEM) (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% FBS, 1mM sodium
pyruvate, 100Uml
 1 penicillin G, 100mgml
 1 streptomycin, 2mM
glutamine, 1mM MEM non-essential amino acids and 50mM 2-
mercaptoethanol in 5% CO2 incubator at 371C. The cells were
dissociated using 0.25% trypsin and 0.53mM EDTA solution and
subcultured once in 3–5 days.
Gliosphere culture
To generate gliospheres, we adopted a culture condition standar-
dized for neurospheres in our laboratory. Briefly, U87MG and
T98G glioblastoma cells were dissociated from DMEM cultures
using trypsin–EDTA solution and cultured in neurobasal medium
(NBM) supplemented with B27 in the presence of 10ngml
 1 bFGF
and EGF. The cells (5 10
4 per ml per well) were cultured in 12-
well plates in 5% CO2 incubator at 371C with a medium change
every 2–3 days and photographed ( 200) after 7–10 days using
AX70 Olympus microscope. To test the effect of PPARg agonists on
gliosphere formation, the cells were cultured in NBM with B27 and
10ngml
 1 bFGF and EGF in the presence of 15d-PGJ2 and ATRA
and photographed ( 200) after 10 days. To test the reversibility of
gliosphere formation, the cells were then cultured in fresh DMEM
medium or NBM with B27 and 10ngml
 1 bFGF and EGF in the
absence of 15d-PGJ2 and ATRA for another 10 days. To determine
the gliosphere counts, U87MG and T98G cells were cultured in
96-well tissue culture plates (5 10
3 per 200ml per well) in NBM
with B27 and 10ngml
 1 EGFþbFGF in the presence of 0, 1, 2.5, 5
and 10mM ciglitazone, 15d-PGJ2 or ATRA for 7–10 days and the
number of gliospheres counted under microscope.
Proliferation assay
Proliferation of glioma and gliosphere cells was measured by
3H
thymidine uptake assay. Briefly, U87MG and T98G glioma and
gliosphere cells were cultured in 96-well tissue culture plates
(1 10
4 per 200ml per well) in NBM supplemented with B27 in the
presence of 0, 1, 5 and 10ngml
 1 EGFþbFGF in 5% CO2
incubator at 371C. The cells were also cultured with 10ngml
 1
EGFþbFGF in the presence of 15d-PGJ2, ciglitazone or ATRA.
3H
thymidine (0.5mCiml
 1) was added after 48h, and the cells were
dissociated and harvested after 72h using a Tomtech harvester 96
(Hamden, CT, USA). The amount of
3H thymidine uptake was
counted on Wallac Microbeta liquid scintillation counter (Perkin
Elmer, Fremont, CA, USA) as a measure of proliferation.
Flow cytometry
The U87MG and T98G glioma and gliosphere cells were cultured in
12-well tissue culture plates in NBM with B27 and 10ngml
 1
EGFþbFGF in the presence of 5mM ciglitazone, 15d-PGJ2 or
ATRA in 5% CO2 incubator at 371C. After 72h, the cells were
harvested, dissociated and incubated in blocking buffer (1% BSA
in PBS) at 41C for 20min. The cells were then stained with PE-
conjugated anti-CD133 antibody or isotype control (1:10; Miltenyi
Biotec) at 41C for 1h. The cells were washed three times with 0.1%
BSA in PBS and analysed by a FACSort flow cytometry using
CellQuest software (Becton Dickinson, San Jose, CA, USA).
Cell cycle analysis
To determine the effect of PPARg agonists on cell cycle
progression, U87MG and T98G gliospheres were cultured in
NBM with B27 and 10ngml
 1 EGFþbFGF in the presence of 5mM
ciglitazone, 15d-PGJ2 or ATRA in 5% CO2 incubator at 371C. After
24h, the gliospheres were dissociated, fixed and permeabilized
with 1% paraformaldehyde and 0.02% Triton X-100 in PBS at 41C
for 20min. The cells were washed in PBS and stored in 70%
ethanol at  201C overnight. After washing in PBS, the cells were
treated with 20mgml
 1 of RNase and stained with 50mgml
 1 of
propidium iodide (Sigma Chemicals Co.) in PBS. The percentage of
cells at different cell cycle stages (G0/G1, G2/M and S phase) was
determined on the basis of DNA content by flow cytometry using
ModFit LT2.0 software.
Apoptosis assay
To determine the effect of PPARg agonists on apoptosis, U87MG
and T98G gliospheres were cultured in neurobasal medium
supplemented with B27 and 10ngml
 1 EGFþbFGF in the
presence of 5mM of 15d-PGJ2, ciglitazone or ATRA in 5% CO2
incubator at 371C for 72h. The cells were washed in PBS and
stained with Annexin V-Flous in binding buffer (0.1 M HEPES/
NaOH, pH 7.4, 1.4 M NaCl, 0.2mm sterile-filtered) containing
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(Roche). The cells were incubated at room temperature for 30min
in the dark and analysed by flow cytometry using Cell Quest
Software. To further determine the extent of apoptosis, the cells
were analysed by terminal deoxynucleotidyl transferase (TdT,
TUNEL) assay according to the manufacturer’s instruction
(Promega, Madison, WI, USA). The cells were fixed in 1%
paraformaldehyde for 20min on ice, washed with PBS and stored
overnight in 70% ethanol at  801C. The samples were then washed
with PBS, and incubated in equilibration buffer for 5min and then
in 50ml of TdT buffer at 371C for 1h. The cells were washed in PBS
and analysed by flow cytometry. To examine DNA fragmentation,
the cells were incubated overnight at 561C in 300ml of digestion
buffer (10mM Tris-HCl, pH 8, 25mM EDTA, pH 8, 0.5% SDS and
0.1mgml
 1 proteinase K) and the genomic DNA was extracted
using phenol/chloroform/isoamyl alcohol (25:24:1) followed by
ammonium acetate/ethanol precipitation. The DNA samples were
dissolved in TE buffer, resolved by 2% agarose gel electrophoresis
and photographed under UV light.
SDS–PAGE and western blot analysis
The U87MG and T98G gliosphere cells were stimulated with 0, 2, 5,
10 and 20ngml
 1 EGFþbFGF in NBMþB27 at 371C for 15min.
The cells were also pretreatmed with 5 and 15mM of ciglitazone,
15d-PGJ2 or ATRA at 371C for 15min and then stimulated with
10ngml
 1 of EGF/bFGF for 15min. The cells were washed in ice-
cold PBS, and the whole cell lysates were prepared by boiling in
lysis buffer (0.2 M Tris-HCl, pH 6.8, 0.8mgml
 1 SDS, 4% glycerol,
0.588 M b-mercaptoethanol, 0.05 M EDTA, 8mgml
 1 bromophenol
blue) for 5min. The whole cell lysates were resolved on 7.5%
SDS PAGE and transferred to nitrocellulose membrane using the
gel electrophoresis and transfer system (Bio-Rad, Hercules, CA,
USA). The residual binding sites in the membrane were blocked by
incubation with TBST (10mM Tris-HCl, pH 8.0, 150mM NaCl and
0.05% Tween 20) containing 3% BSA for 1h. The blots were
washed three times in TBST at room temperature and incubated
with anti-phospho-Tyk2 (1:1000), anti-phospho-Stat3 (1:2000) or
anti-b-actin (1:5000) antibody in TBST containing 1% BSA at 41C
overnight. The membranes were then washed with TBST and
incubated with peroxidase-conjugated anti-IgG antibody in TBST
(1:10000) for 1h. The blots were developed by enhanced
chemiluminescence (ECL) detection system and film (Amersham
Life Sciences, Arlington Heights, IL, USA) according to the
manufacturer’s instruction. The gliospheres were also cultured in
six-well plates in the presence of 5mM of 15d-PGJ2, ciglitazone,
ATRA or DMSO control for 48h and the cell lysates were analysed
by western blot using anti-PPAR-g antibody (1:1000) and
peroxidase-conjugated anti-IgG antibody (1:10000) for 1h and
visualised by ECL detection system.
Quantitative reverse transcription PCR
The U87MG and T98G gliospheres were cultured in six-well plates
(2 10
6 cells per well) in NBMþB27 with 10ngml
 1 EGFþbFGF
in the presence of 5mM of 15d-PGJ2, ciglitazone or ATRA. After
36h, the cells were harvested and the total RNA was extracted
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instruction. The cDNA was reverse-transcribed
by incubating 5mg of total RNA in 10ml of reaction mixture of
random hexamer primers and master mix from TaqMan reverse
transcription kit (Applied Biosystems, Branchburg, NJ, USA). For
quantitative real-time PCR, 2ml of the cDNA (equivalent to 0.1mg
total RNA) was amplified in TaqMan Universal Master Mix with
optimised concentrations of PPARg primer sets and probes in a
fast optical 96-well reaction plate using the 7900 Fast Sequence
Detection Real-time PCR System (Applied Biosystems, Foster City,
CA). The results were analysed using the Prism 7900 relative
quantification (DDCt) study software (Applied Biosystems, Foster
City, CA). The level of PPARg was normalised to GAPDH and
expressed as arbitrary fold change compared with control sample.
Statistical analysis
The experiments were repeated three or more times and the data
were analysed by ANOVA (Graphpad Prism 5.0). The P-values less
than 0.05 were considered significant.
RESULTS
PPARc agonists inhibit EGFþbFGF-induced gliosphere
formation in culture
To study the effect of PPARg agonists on the expansion of BTSCs
from glioma, we first established culture conditions to generate
gliospheres in vitro. As shown in Figure 1, in vitro culture of T98G
and U87MG human glioma cells grow as monolayer in DMEM
medium with 10% FBS (a1, e1). But in vitro culture of glioma cells
in NBMþB27 with EGFþbFGF promotes gliosphere formation in
5–7 days that increase in size by 7–10 days (b1, f1). Interestingly,
in vitro treatment with PPARg agonist 15d-PGJ2 or ATRA resulted
in a significant decrease in the number and size of gliospheres in
T98G (c1, d1) and U87MG cells (g1, h1), suggesting that PPARg
agonists inhibit gliosphere formation in culture. The U87MG and
T98G gliospheres grow as monolayer after subculture in DMEM
with 10% FBS (b2, f2). On the other hand, subculture of 15d-PGJ2-
or ATRA-treated T98G cells (c2, d2) and U87MG cells (g2, h2) in
fresh NBM with EGFþbFGF in the absence of nuclear receptor
agonists resulted in gliosphere formation in 7–10 days. Further
analyses showed that in vitro treatment with 15d-PGJ2, ciglitazone
or ATRA resulted in a dose-dependent decrease in the number of
gliospheres generated from T98G and U87MG cells following
culture in NBM with B27 and EGFþFGF. These results suggest
that PPARg agonists inhibit EGFþbFGF-induced gliosphere
formation in culture.
PPARc agonists inhibit EGFþbFGF-induced expansion of
CD133þ gliosphere cells in culture
As CD133 has been used as a marker to identify BTSCs, we
analysed the presence of CD133-positive cells in gliospheres
generated in culture. As shown in Figure 2, U87MG and T98G
cells show very low levels of CD133þ BTSCs, which increased
significantly in gliospheres. However, the U87MG and T98G cells
cultured in DMEM showed 20 and 16.8% CD133þ cells with a
mean fluorescence intensity (MFI) of 16 and 15 that increased to
58 and 52% with an MFI of 21 and 20, respectively, following
culture as gliospheres (Figure 2A). Interestingly, in vitro treatment
with PPARg agonists resulted in a significant decrease in the
number of CD133þ cells in gliospheres. In this experiment,
however, the U87MG-spheres showed 75% CD133þ BTSCs with
an MFI of 31 that decreased to 33, 13 and 11% with an MFI of 24,
19 and 18 following treatment with ciglitazone, 15d-PGJ2 or ATRA,
respectively (Figure 2B–D). Similarly, T98G-gliospheres showed
60% CD133þ BTSCs with an MFI of 24 that decreased to 15, 12
and 7% with an MFI of 16, 14 and 13 following treatment with
ciglitazone, 15d-PGJ2 or ATRA, respectively (Figure 2B–D). These
results suggest that PPARg agonists and retinoic acid inhibit the
expansion of CD133þ BTSCs in culture.
PPARc agonists inhibit EGFþbFGF-induced proliferation
of gliosphere cells
To test the anti-tumour activity of PPARg agonists on BTSCs, we
measured cell proliferation in culture. As shown in Figure 3,
in vitro culture of U87MG (a), T98G (b), U87MG-gliosphere (c)
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sand T98G-gliosphere (d) cells in NBMþB27 with EGFþbFGF
induced a dose-dependent increase in proliferation, with a
significantly higher response in gliosphere cells. Interestingly,
PPARg agonists induced a strong dose-dependent inhibition of
proliferation in both glioma and gliosphere cells. In vitro culture of
U87MG-gliosphere cells in NBMþB27 with EGFþFGF in the
presence of ciglitazone (g), 15d-PGJ2 (k) or ATRA (o) resulted in
21, 86 and 92% inhibition of proliferation, respectively. Similarly,
T98G-gliosphere cells cultured in NBMþB27 with EGFþFGF in
the presence of ciglitazone (h), 15d-PGJ2 (l) or ATRA (p) resulted
DMEM
T98G
U87MG
DMEM
DMEM
DMEM DMEM
DMEM NBM
NBM
NBM NBM
NBM
NBM NBM+15d-PGJ2
NBM+15d-PGJ2
NBM+ATRA
NBM+ATRA
200 m 200 m 200 m 200 m
200 m
200 m
200 m
200 m 200 m
200 m 200 m
200 m 200 m 200 m 200 m
200 m
A1
A2
B1 C1 D1
D2 C2 B2
E1 F1 G1 H1
H2 G2 F2 E2
150
100
50
0
0 1.0 2.5 5.0
U87MG T98G
∗∗∗
∗∗∗ ∗∗∗ ∗∗∗
∗∗∗
∗∗∗ ∗∗∗
∗∗∗ ∗∗∗
∗∗∗
∗∗∗
∗∗∗
∗∗∗
∗∗∗
∗∗∗
∗∗∗
∗∗∗
∗∗∗
∗∗∗
∗∗∗
∗∗∗
∗∗∗ ∗∗∗ ∗∗∗
Ciglitazone
15d-PGJ2
ATRA
Ciglitazone
15d-PGJ2
ATRA
N
u
m
b
e
r
 
o
f
 
g
i
l
o
s
p
h
e
r
e
s
N
u
m
b
e
r
 
o
f
 
g
i
l
o
s
p
h
e
r
e
s
10.0
150
100
50
0
0 1.0 2.5 5.0 10.0
PPAR- agonists (M) PPAR- agonists (M)
Figure 1 Inhibition of gliosphere formation by PPARg agonists. The T98G and U87MG human glioblastoma cells were cultured in DMEM medium with
10% FBS (A1 and E1) or NBM with B27 and 10ngml
 1 EGFþbFGF in the absence (B1 and F1) or presence of 1.0mM 15d-PGJ2 (C1 and G1) or ATRA
(D1 and H1) and photographed ( 200) after 10 days. The cells were then cultured in fresh DMEM medium with 10% FBS (A2, B2 and E2, F2) or NBM
with B27 and 10ngml
 1 EGFþbFGF in the absence of 15d-PGJ2 (C2 and G2) or ATRA (D2 and H2) and photographed ( 200) after 10 days. The
T98G and U87MG cells were also cultured in NBM with B27 and EGFþbFGF in the absence or presence of Ciglitazone, 15d-PGJ2 and ATRA, the number
of gliospheres counted after 10 days and the mean±s.e.m. of triplicates presented in the histogram. The P-values are shown as (*Po0.05), (**Po0.01) and
(***Po0.001) and the figure is a representative for three independent experiments.
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Moreover, in vitro treatment of U87MG glioma cells with
ciglitazone (e), 15d-PGJ2 (i) or ATRA (m) cultured in NBMþB27
with EGFþFGF resulted in 46, 72.26 and 81% inhibition of
proliferation, respectively. Similarly, in vitro treatment of T98G
glioma cells with ciglitazone (f), 15d-PGJ2 (j) or ATRA (n) cultured
in NBMþB27 with EGFþFGF resulted in 44, 65 and 78%
inhibition of proliferation, respectively. These results suggest that
PPARg agonists inhibit proliferation of BTSCs in culture.
PPARc agonists induce cell cycle arrest in gliosphere cells
We then examined whether the inhibition of proliferation by
PPARg agonists was due to cell cycle arrest or apoptosis in
gliospheres. As shown in Figure 4A, treatment of T98G and
U87MG-derived gliosphere cells with ciglitazone, 15d-PGJ2 or
ATRA resulted in cell cycle arrest at G0/G1 phase. U87MG-sphere
cells cultured in NBMþB27 with EGFþbFGF showed 48% G0/G1
cells, 21% G2/M cells and 31% S-phase cells; however, addition of
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Figure 2 Inhibition of CD133þ BTSC expansion by PPARg agonists. The U87MG and T98G-sphere cells were cultured in NBMþB27 with EGFþFGF
in the absence (A) or presence of 1mM ciglitazone (B), 15d-PGJ2 (C) or ATRA (D). After 5 days, the cells were stained with anti-CD133-PE or isotype-
matched control antibody and analysed by flow cytometer. The percentage of CD133þ cells and mean fluorescence intensity in brakets are shown.
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s5mM ciglitazone, 15d-PGJ2 or ATRA resulted in 59, 59 and 55% G0/
G1 cells, 25, 10 and 24% G2/M cells and 16, 32 and 22% S-phase
cells in 24h. Similarly, T98G-sphere cells cultured in NBMþB27
with EGFþbFGF showed 57% G0/G1 cells, 12% G2/M cells and
31% S-phase cells, and the addition of 5mM ciglitazone, 15d-PGJ2
or ATRA resulted in 64, 66 and 72% G0/G1 cells, 11, 5 and 6%
G2/M cells and 32, 23 and 22% S-phase cells in 24h. These results
suggest that PPARg agonists regulate cell cycle progression of
BTSCs in culture.
PPARc agonists induce apoptosis in gliosphere cells
We then examined whether PPARg agonists induce apoptosis in
BTSCs. As shown in Figure 4B, U87MG- and T98G-gliosphere cells
cultured in NBMþB27 with EGFþbFGF showed low apoptotic
cell death. However, treatment with PPARg agonists resulted in a
significant increase in apoptotic cells as measured by Annexin V
staining. U87MG-gliosphere cells cultured in NBMþB27 with
EGFþbFGF showed 5% apoptosis that increased to 7, 7 and 8%
following the addition of 5mM ciglitazone, 15d-PGJ2 or ATRA,
respectively. Similarly, T98G-sphere cells cultured in NBMþB27
with EGFþbFGF showed 9% apoptosis that increased to 15, 16
and 17% following the addition of 5mM ciglitazone, 15d-PGJ2
or ATRA, respectively. To further confirm the results, we
performed Tunel assay in gliosphere cells following treatment
with PPARg agonists. As shown in Figure 4C, U87MG-sphere
cells cultured in NBMþB27 with EGFþbFGF showed 0%
apoptosis that increased to 11, 16 and 19% following the addition
of 5mM ciglitazone, 15d-PGJ2 or ATRA, respectively. Similarly,
T98G-sphere cells cultured in NBMþB27 with EGFþbFGF
showed 0% apoptosis that increased to 7, 16 and 26% following
the addition of 5mM ciglitazone, 15d-PGJ2 or ATRA, respectively.
Further analysis by agarose gel electrophoresis showed that
U87MG and T98G-gliosphere cells treated with 5mM ciglitazone,
15d-PGJ2 or ATRA, but not in control samples, showed the
evidence of DNA fragmentation (Figure 4D). These results
suggest that PPARg agonists induce modest apoptosis of BTSCs
in culture.
PPARc agonists inhibit EGF/bFGF-induced Jak-Stat
pathway in gliosphere cells
To study the mechanisms in the regulation of BTSCs by PPARg
agonists, we examined their effects on EGFþbFGF-induced
activation of Jak-Stat signalling pathway. As shown in Figure 5A,
in vitro stimulation of T98G-sphere cells with EGFþbFGF induced
the tyrosine phosphorylation of Tyk2 and Stat3 in 15min in a
dose-dependent manner. Interestingly, pretreatment with 15d-
PGJ2, ciglitazone or ATRA for 15min resulted in a dose-dependent
decrease in the tyrosine phosphorylation of Tyk2 and Stat3 in
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Figure 3 Inhibition of BTSC proliferation by PPARg agonists. The U87MG and T98G cells (A, B) and the gliosphere cells (C, D) were cultured in
NBMþB27 with different concentrations of EGFþFGF. The U87MG and T98G cells were cultured in NBM with B2 and 10ngml
 1 bFGFþEGF in the
presence of ciglitazone (E, F), 15d-PGJ2 (I, J) or ATRA (M, N) in 96-well tissue culture plates in triplicate. U87MG- and T98G-gliosphere cells were also
cultured in NBMþB27 with 10ngml
 1 EGFþFGF in the presence of ciglitazone (G, H), 15d-PGJ2 (K, L) or ATRA (O, P). After 48h,
3H thymidine
(0.5mCi per well) was added, and the amount of
3H thymidine uptake was counted on a Perkin Elmer Microbetaplate liquid scintillation counter as a
measure of proliferation. The values are mean of triplicate (±s.e.m.) with P-values shown as (*Po0.05), (**Po0.01) and (***Po0.001). The figure is
representative of three independent experiments.
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Figure 4 Induction of cell cycle arrest and apoptosis by PPARg agonists in BTSCs. U87MG and T98G-sphere cells (2 10
6 cells) were cultured in NBM
with B27 and EGFþFGF in the presence of 1mM ciglitazone, 15d-PGJ2 or ATRA. The cells were harvested after 48h and stained with propidium iodide (A),
Annexin V-FITC (B) or dUTP-FITC (C) and analysed by flow cytometry. Genomic DNA was extracted and analysed by agarose gel electrophoresis to
visualise DNA fragmentation (D). The figure is representative of three independent experiments.
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tion, treatment with 15mM agonists resulted in almost complete
inhibition of Tyk2 and Stat3 phosphorylation in gliosphere cells.
These results suggest that PPARg agonists inhibit the expansion of
BTSCs by targeting EGFþFGF-induced Tyk2-Stat3 signalling
pathway.
PPARc agonists induce the expression of PPARc in
gliosphere cells
To further understand the mechanisms in the regulation of BTSCs
by PPARg agonists, we examined the expression of PPARg and its
regulation by agonists in gliosphere cells. As shown in Figure 5B,
real-time PCR analysis showed that T98G-sphere cells cultured in
NBMþB27 with EGFþbFGF showed detectible levels of PPARg
mRNA expression that increased significantly following treatment
with 5mM ciglitazone, 15d-PGJ2 or ATRA for 36h in culture.
Western blot analysis showed that T98G-sphere cells cultured in
NBMþB27 with EGFþbFGF showed detectible levels of PPARg
protein that increased significantly following treatment with 5mM
ciglitazone, 15d-PGJ2 or ATRA for 48h in culture. These results
suggest that BTSCs express functionally active PPARg, and the
expression levels are increased following treatment with PPARg
agonists in culture.
DISCUSSION
The identification of tumour stem cells has revolutionized the
basic understanding of the biology, drug discovery and treatment
of cancer. Although CD133 has been commonly used as a marker
to identify BTSCs, many tumours often present a small population
of CD133þ cells, making it difficult to isolate sufficient cells for
drug discovery. In this study, we approached to expand the BTSC
population as gliospheres from U87MG and T98G human
glioblastoma cells according to a protocol standardized in our
laboratory. We found that in vitro culture of human glioblastoma
cells with EGFþbFGF induced the generation of gliospheres with
more than 50% of cells positive for CD133, suggesting the
successful expansion of BTSCs in culture. Interestingly, treatment
with PPARg agonists resulted in a reversible inhibition of
gliosphere formation in culture. Peroxisome proliferator-activated
receptor gamma agonists also inhibited the proliferation of BTSCs
by inducing cell cycle arrest and apoptosis. The induction of
growth arrest and apoptosis by PPARg agonists was associated
with the expression of PPARg and inhibition of Tyk2-Stat3
signalling pathway in BTSCs, further suggesting the use of PPARg
agonists in the treatment of brain tumours.
Epidermal growth factor and FGF are two important growth
factors that induce the expansion of BTSCs as gliospheres in
culture. Epidermal growth factor receptor (EGFR) is a 170kDa
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Figure 5 Inhibition of EGF/FGF signalling and induction of PPARg expression by PPARg agonists in BTSCs. T98G-sphere cells (2 10
6 cells) were
cultured in NBM with B27 and EGFþFGF in the absence or presence of ciglitazone, 15d-PGJ2 or ATRA. The cells were harvested after 15min and the
whole cell lysates were analysed by SDS–PAGE and western blot using phosphospecific Tyk2 or Stat3 antibodies and visualised by ECL detection system
(A). The cells were harvested after 36h and total RNA was analysed for the expression of PPARg by real-time RT–PCR using GAPDH as internal control
(B). The values are mean of triplicate (±s.e.m.) and P-values shown as (*Po0.05) in the figure. The cells were harvested after 48h and total protein was
analysed for the expression of PPARg analysed by SDS–PAGE and western blot using anti-PPARg antibodies and visualised by ECL detection system (C).
The figure is representative of three independent experiments.
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stransmembrane tyrosine kinase that binds to EGF (Wells, 1999;
Johnston et al, 2006) and mediates signalling pathways leading to
survival, proliferation, migration and invasion of glioma cells
(Wells, 1999). The expression of EGFR is often amplified in human
glioma, but is undetectable or weakly expressed in normal brain
(Martens et al, 2008). Fibroblast growth factor-2 (bFGF) is a
ubiquitously expressed prototype of the family of 20 proteins
(Szebenyi and Fallon, 1999) with mitogenic, angiogenic, neuro-
trophic and oncogenic activities (Zagzag et al, 1990). Fibroblast
growth factor-2 plays a critical role in nervous system development
(Eckenstein, 1994), and dysregulated expression is implicated in
the pathogenesis of brain tumours. FGF-2 is upregulated during
reactive gliosis (Finklestein et al, 1988; Frautschy et al, 1991) and
overexpressed in malignant gliomas (Murphy et al, 1989; Morrison
et al, 1994). The expression level of FGF-2 correlates with tumour
grade, extent of anaplasia and clinical outcomes in glioma
(Takahashi et al, 1992; Bredel et al, 1997). Thus EGF and FGF
receptors are now considered as prime targets for the specific
delivery of a variety of diagnostic and therapeutic agents (Johnston
et al, 2006; Baguma-Nibasheka et al, 2007; Fukushima et al, 2008).
However, the role of EGF and bFGF and their receptors on growth
and expansion of BTSCs are not well defined. In this study, we
showed that EGFþbFGF induce the expansion of CD133þ BTSCs
as gliospheres in culture. Recent studies have shown that tumour
environment dictates cancer stem cell expression and invasive
phenotype in vivo (Annabi et al, 2008). Although the exact
mechanisms are not known, it is most likely that the growth factors
induce the expansion of CD133þ BTSCs or de-differentiation of
glioblastoma cells to CD133þ BTSCs in culture (Kondo, 2007).
Earlier studies have shown that PPARg agonists induce growth
arrest and apoptosis in glioblastoma cells in culture (Liu et al,
2004; Morosetti et al, 2004). In this study, we show for the first
time that PPARg agonists inhibit the generation of gliospheres and
expansion of CD133þ BTSCs in culture.
Drugs that reduce cell proliferation and survival has high
therapeutic potential in human tumours. Earlier studies have
shown that PPARg agonists induced growth arrest and apoptosis in
glioblastoma cells without affecting primary astrocytes (Zander
et al, 2002), demonstrating its anti-neoplastic potency in humans.
In this study, we found that PPARg agonists induce a strong and
dose-dependent inhibition of proliferation in gliosphere cells in
culture. The PPARg agonists also induced a modest cell cycle arrest
and apoptosis in gliosphere cells, suggesting their anti-tumour
activity in BTSCs. The exact mechanisms how PPARg agonists
induce growth arrest and apoptosis in BTSCs are not known.
Signalling through its receptor tyrosine kinase, EGF and bFGF
induce the activation of Jak-Stat pathway leading to proliferation
and survival of different cell types (Raz et al, 1999; Burdon et al,
2002). We have shown earlier that PPARg agonists inhibit
cytokine-induced activation of Jak-Stat pathway in immune cells
and LIF-induced activation of Jak-Stat pathway in mouse
embryonic stem cells (Rajasingh and Bright, 2006). In this study,
we found that EGFþbFGF induces tyrosine phosphorylation of
Stat3 and Tyk2, and PPARg agonists inhibit tyrosine phosphoryla-
tion of Stat3 and Tyk2 in both U87MG and T98G-gliosphere cells.
The inhibition of Stat3 proteins by PPARg agonists may be due to
the inhibition of upstream Tyk2 or its direct effect on Stat3
protein. Peroxisome proliferator-activated receptor gamma ago-
nists can also regulate Tyk2-Stat3 pathway by activating the
negative regulators, such as suppressor of cytokine signalling or
SHP-1 proteins in BTSCs (Park et al, 2003). Although the possible
inhibition of other growth signalling pathways by PPARg agonists
cannot be ruled out, our results suggest that the inhibition of
Jak-Stat pathway be an important mechanism by which PPARg
agonists induces growth arrest and apoptosis in BTSCs.
Earlier studies have shown that glioma cells express PPARg
and that the levels of expression can be modulated by specific
agonists (Morosetti et al, 2004). In this study, we showed that the
gliosphere cells express detectible levels of PPARg mRNA and
protein and that treatment with PPARg agonists increased the
expression, suggesting its functional significance to BTSCs and the
involvement of PPARg-dependent mechanisms in the induction of
growth arrest and apoptosis by PPARg agonists in BTSCs.
Although the precise molecular basis of the antineoplastic
mechanisms of PPARg agonists is not fully understood, our
findings suggest that the clinically used PPARg agonists may offer
new therapies to target BTSCs for the treatment of brain tumours
in patients.
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